iCAD Showcases ProFound AI™ Platform at European Society of Breast Imaging Annual Scientific Meeting in Budapest
Company to exhibit
ProFound AI for 2D and 3D Mammography in Europe
Nashua, N.H. and Budapest, Hungary – October 1, 2019 – iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions,
today announced the Company will exhibit the ProFound AI™ platform, including
ProFound AI™ for 2D Mammography and ProFound AI™ for Digital Breast
Tomosynthesis (DBT) in the iCAD exhibition booth (#13) at
the European Society of Breast Imaging (EUSOBI) meeting in Budapest, Hungary,
from October 3-5, 2019. ProFound AI for DBT was CE Marked in March 2018 and FDA
cleared in December 2018; ProFound AI for 2D Mammography was CE Marked in July
2019 and recently launched in Europe.
The ProFound AI platform is a high-performing workflow solution built on the latest deep-learning artificial
intelligence technology. In a recent study published in Radiology: Artificial Intelligence, ProFound AI for DBT was found to improve breast
cancer detection rates by 8 percent, reduce unnecessary recall rates by 7.2
percent, and slash reading time for radiologists
by 52.7 percent.1
“ProFound AI was trained on one of the largest available datasets
and is the first and only software for DBT that is clinically proven to
increase sensitivity and specificity, while reducing reading time for
radiologists,” said Michael Klein, Chairman and CEO of iCAD. “ProFound AI
continues to grow in adoption across Europe, and now with the launch of
ProFound AI for 2D Mammography, even more radiologists are discovering the
clinical benefits ProFound AI offers to both their departments and their
patients.”
The software rapidly and accurately analyzes each
tomosynthesis image, detecting both malignant soft tissue densities and
calcifications with accuracy. It provides radiologists
with Certainty of Finding lesion and Case Scores, which assists in
clinical decision-making and prioritizing caseloads. Featuring the latest in deep-learning artificial intelligence, the platform also allows for
continuously improved performance via ongoing updates.
“I’ve worked with
ProFound AI for over a year now and I have seen significant improvements in the
detection of breast cancers, especially in complicated cases,” according to Axel
Gräwingholt, MD, Radiologie am Theater, Paderborn, Germany. “With such a high sensitivity and
specificity, ProFound AI often reveals suspicious areas that may have been
missed, and at the same time, reassures my decisions when no further patient
procedures are needed.”
Leading experts will be available in the
iCAD booth throughout the meeting to provide their clinical experience using
the technology, including Dr. Gräwingholt. ProFound AI
will also be featured in an EUSOBI Workshop titled “ProFound AI for GE DBT” on
Friday, October 4, from 12:15-13:15 in Room Liszt 3.
For more information, visit www.icadmed.com.
Reference:
- Conant, E. et al. (2019). Improving
Accuracy and Efficiency with Concurrent Use of Artificial Intelligence for
Digital Breast Tomosynthesis. Radiology: Artificial Intelligence.1 (4). Accessed
via https://pubs.rsna.org/doi/10.1148/ryai.2019180096
About iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global medical technology leader
providing innovative cancer detection and therapy solutions. For more
information, visit www.icadmed.com.
“Safe Harbor” Statement under the Private Securities
Litigation Reform Act of 1995
Certain statements contained in this News Release constitute
“forward-looking statements” within the meaning of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements involve a number
of known and unknown risks, uncertainties and other factors which may cause the
actual results, performance or achievements of the Company to be materially
different from any future results, performance or achievements expressed or
implied by such forward-looking statements. Such factors include, but are not
limited, to the Company’s ability to defend itself in litigation matters, to
achieve business and strategic objectives, the risks of uncertainty of patent
protection, the impact of supply and manufacturing constraints or difficulties,
uncertainty of future sales levels, protection of patents and other proprietary
rights, the impact of supply and manufacturing constraints or difficulties,
product market acceptance, possible technological obsolescence of products,
increased competition, litigation and/or government regulation, changes in
Medicare or other reimbursement policies, risks relating to our existing and
future debt obligations, competitive factors, the effects of a decline in the
economy or markets served by the Company; and other risks detailed in the
Company’s filings with the Securities and Exchange Commission. The words
“believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,”
“anticipate,” “likely,” “seek,” and similar expressions identify
forward-looking statements. Readers are cautioned not to place undue reliance on
those forward-looking statements, which speak only as of the date the statement
was made. The Company is under no obligation to provide any updates to any
information contained in this release. For additional disclosure regarding
these and other risks faced by iCAD, please see the disclosure contained in our
public filings with the Securities and Exchange Commission, available on the
Investors section of our website at http://www.icadmed.com and on the SEC’s website
at http://www.sec.gov.
Contacts:
Media inquiries:
Jessica Burns, iCAD
+1-201-423-4492
FP2COM
Florence Portejoie
Tel : + 33 6 07 76
82 83 France
Investor Relations:
LifeSci Advisors, on behalf of iCAD, Inc.
Jeremy Feffer, +1-212-915-2568